Article citationsMore>>

EMD Serono (2016) An Open-Label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-Term Follow-Up Data in Subjects with Relapsing Multiple Sclerosis Treated with Atacicept for up to 5 Years (ATAMS-Extension). NCT00853762.

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top